Antibody-Mediated Killing of Carbapenem-Resistant ST258 Klebsiella pneumoniae by Human Neutrophils

Scott D. Kobayashi,a Adeline R. Porter,a Brett Freedman,a Ruchi Pandey,b Liang Chen,b Barry N. Kreiswirth,b Frank R. DeLeoa

aLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
bPublic Health Research Institute Tuberculosis Center, New Jersey Medical School-Rutgers University, Newark, New Jersey, USA

ABSTRACT Carbapenem-resistant Klebsiella pneumoniae is a problem worldwide. A carbapenem-resistant K. pneumoniae lineage classified as multilocus sequence type 258 (ST258) is prominent in the health care setting in many regions of the world, including the United States. ST258 strains can be resistant to virtually all clinically useful antibiotics; treatment of infections caused by these organisms is difficult, and mortality is high. As a step toward promoting development of new therapeutics for ST258 infections, we tested the ability of rabbit antibodies specific for ST258 capsule polysaccharide to enhance human serum bactericidal activity and promote phagocytosis and killing of these bacteria by human neutrophils. We first demonstrated that an isogenic wzy deletion strain is significantly more susceptible to killing by human heparinized blood, serum, and neutrophils than a wild-type ST258 strain. Consistent with the importance of capsule as an immune evasion molecule, rabbit immune serum and purified IgG specific for ST258 capsule polysaccharide type 2 (CPS2) enhanced killing by human blood and serum in vitro. Moreover, antibodies specific for CPS2 promoted phagocytosis and killing of ST258 by human neutrophils. Collectively, our findings suggest that ST258 CPS2 is a viable target for immunoprophylactics and/or therapeutics.

IMPORTANCE Infections caused by carbapenem-resistant K. pneumoniae are difficult to treat, and mortality is high. New prophylactic approaches and/or therapeutic measures are needed to prevent or treat infections caused by these multidrug-resistant bacteria. A strain of carbapenem-resistant K. pneumoniae, classified by multilocus sequence typing as ST258, is present in many regions of the world and is the most prominent carbapenem-resistant K. pneumoniae lineage in the United States. Here we show that rabbit antibodies specific for capsule polysaccharide of ST258 significantly enhance human serum bactericidal activity and promote phagocytosis and killing of this pathogen by human neutrophils. These studies have provided strong support for the idea that development of an immunotherapy (vaccine) for carbapenem-resistant K. pneumoniae infections is feasible and has merit.

KEYWORDS Klebsiella, antibiotic resistance, antibody, carbapenems, neutrophils, vaccines

Klebsiella pneumoniae is a commensal bacterium of the intestine, but it can cause infections in individuals with significant comorbidities and/or risk factors, such as major surgery or immunosuppression. Infections caused by K. pneumoniae are primarily hospital-associated infections. Magill et al. reported that K. pneumoniae and K. oxytoca together caused ~10% of all infections among 183 United States hospitals tested (1). These infections included respiratory tract infections (pneumonia), surgical site infections, urinary tract infections, and bloodstream infections (1). The problem of the high
burden of infections caused by Klebsiella spp. is compounded by antibiotic resistance. Although K. pneumoniae is known historically for its resistance to β-lactam antibiotics, the worldwide emergence of carbapenem-resistant K. pneumoniae strains that are susceptible only to colistin, tigecycline, and/or gentamicin is a major concern (2, 3). In addition, some strains of carbapenem-resistant K. pneumoniae are resistant to all clinically relevant antibiotics and treatment of infections caused by such organisms is difficult (4). Mortality associated with infections caused by carbapenem-resistant K. pneumoniae is relatively high (e.g., ~30% to ~48% in selected studies of bloodstream infections) (5–7), and new approaches for prophylaxis or treatment are needed.

A carbapenem-resistant K. pneumoniae strain classified by multilocus sequence typing as sequence type 258 (ST258) remains the most prominent lineage in United States hospitals (8–10). Carbapenem resistance in ST258 is conferred by K. pneumoniae carbapenemase (KPC), which is encoded by blaKPC within a transposon (Tn4401) that is present on a plasmid (11). Recent genome analyses indicate that the two major clades of ST258 encode different capsule polysaccharide (CPS) types by gene clusters known as cps-1 and cps-2 (12–14). These two capsule types remain predominant among ST258 clinical isolates worldwide, and cps-2 isolates are more abundant than cps-1 isolates in many geographic regions (10, 13, 15–17). The contribution of CPS to the success of ST258 outside antibiotic resistance remains incompletely determined.

We demonstrated previously that cps-1 or cps-2 ST258 clinical isolates are largely resistant to phagocytosis by human neutrophils but that any ingested bacteria are killed readily (18). Moreover, optimal killing of ST258 by serum complement occurs in the presence of naturally occurring immunoglobulin G (IgG) (19). In aggregate, those and other previous studies provided support to the idea that immunotherapy (a vaccine approach) can be considered for prevention/treatment of infections caused by carbapenem-resistant K. pneumoniae (20). As a first step toward testing the validity of an immunotherapy approach, we generated antibodies specific for CPS1 and CPS2 of ST258 clinical isolates and tested their ability to enhance serum bactericidal activity and promote phagocytosis and killing by human neutrophils.

RESULTS AND DISCUSSION

ST258 CPS contributes to evasion of innate host defense. CPS is known to contribute to K. pneumoniae virulence, a characteristic attributed largely to resistance to complement-mediated killing and phagocytosis (21–24). The roles played by K. pneumoniae CPS are varied and strain specific (23, 25, 26). A gene known as wzy is required for capsule biosynthesis in many species of bacteria, including K. pneumoniae (27–29). Previous studies performed with serotype K1 K. pneumoniae strains demonstrated that a wzy-like gene known as magA confers resistance to serum complement and phagocytosis (28, 30, 31). As a first step toward determining whether CPS has contributed to the success of ST258 as a human pathogen, we evaluated the survival rates of wild-type and isogenic cps-2 mutant (Δwzy) ST258 strains in human blood and serum in vitro. Compared to that seen with the wild-type ST258 strain, the survival of the Δwzy ST258 strain was reduced significantly in human blood and serum (e.g., the survival rates in 100% serum were 73.7% ± 13.6% for the wild-type strain and 0.1% ± 0.03% for the mutant strain; P < 0.05) (Fig. 1A to C). Survival of the Δwzy strain in heparinized blood and serum was restored fully by complementation with wzy expressed from a plasmid (Fig. 1A to C).

We next compared levels of phagocytosis and killing of wild-type and Δwzy ST258 strains by human neutrophils (Fig. 1D and E). Consistent with the ability of CPS to inhibit complement function, the Δwzy ST258 strain was ingested and killed by neutrophils to a significantly greater extent than the wild-type or complemented mutant strains (Fig. 1D and E). Taken together, these results indicate that the ST258 CPS contributes to evasion of innate host defenses and thereby promotes survival in humans.

Generation of capsule-specific rabbit antibodies. Inasmuch as the majority of carbapenem-resistant ST258 K. pneumoniae clinical isolates in the United States can be
classified as cps-1 or cps-2 (13), we used purified CPS1 and CPS2 from representative ST258 clinical isolates to generate rabbit polyclonal antiserum specific for cps-1 and/or cps-2 strains (Fig. 2). CPS preparations were highly immunogenic, and antiserum from rabbits immunized with either CPS1 (anti-CPS1) or CPS2 (anti-CPS2) contained antibodies that bound the surface of multiple cps-1 or cps-2 isolates (Fig. 2A to C). Although there was recognition (albeit limited) of cps-1 isolate 50219 with anti-CPS2 (Fig. 2D; compare upper and lower panels), anti-CPS1 failed to bind NJST258_2, a representative cps-2 isolate (Fig. 2E). These results were verified in preliminary flow cytometry assays performed with 2 additional cps-1 isolates (34440 and 29940) and cps-2 isolates (NJST258_1 and 33576) and are likely explained by differences noted in the compositions of CPS1 and CPS2 (see Table S1 in the supplemental material).

**CPS antibodies promote serum bactericidal activity.** We demonstrated previously that cps-1 and cps-2 ST258 clinical isolates have generally comparable survival rates in normal human serum (NHS) (19). That said, a subset of those isolates (3 of 20), including NJST258_1 (cps-2), were killed in 5% NHS (19). Depletion of IgG from human serum increased survival of this isolate, providing support to the idea that naturally occurring antibodies promote complement-mediated killing of ST258 (19). Indeed, serum from healthy blood donors contained IgG and/or IgM that bound to the surface of cps-1 or cps-2 isolates (see Fig. S1 in the supplemental material). To determine whether anti-CPS1 and anti-CPS2 contain antibodies that promote complement-mediated killing of ST258, we tested the ability of 1% anti-CPS1 or anti-CPS2 to augment bactericidal activity of NHS (Fig. 3). Consistent with the ability of IgG to promote deposition of complement and formation of the membrane attack complex, serum bactericidal activity was enhanced significantly by anti-CPS2 in the presence of 5% and/or 10% NHS (Fig. 3A and B). The ability of anti-CPS1 to augment bactericidal activity of NHS was limited by comparison (compare panels A and B in Fig. 3). This
finding was surprising to us, since the titer of anti-CPS1 (~64,000), which was evaluated by flow cytometry with live bacteria, was greater than that of anti-CPS2 (~16,000). In addition, this cps-1 isolate (50219) is killed at significant levels in 25% NHS and is therefore not fully resistant to complement-mediated bactericidal activity (Fig. 3A). The findings determined with immune serum were recapitulated by using IgG purified from anti-CPS1 or anti-CPS2 (Fig. 3C and D). The limited ability of anti-CPS1 and IgG anti-CPS1 IgG to augment the bactericidal activity of NHS was not likely related to the
presence of (or to competition with) naturally occurring antibodies in NHS or unique to isolate 50219, since the results were similar with normal rabbit serum (Fig. 3E and F) or with another cps-1 isolate (34446; survival was 100.7% ± 14.4% versus 104.0% ± 30.2% in 5% NHS containing 100 μg/ml nonimmune [NI] IgG versus 100 μg/ml anti-CPS1 IgG; n = 3). Taken together, these findings demonstrate that antibody specific for CPS2 enhances serum bactericidal activity.

**Capsule-specific antibody promotes phagocytosis and killing of ST258 by human neutrophils.** We next tested the ability of IgG purified from anti-CPS1 or
anti-CPS2 to enhance binding and phagocytosis of ST258 by human neutrophils. Although we reported previously that there was limited neutrophil phagocytosis of cps-1 and cps-2 isolates (18), isolate 50219 (cps-1) was not among those tested. Unexpectedly, 50219 was bound and ingested by human neutrophils cultured in NHS alone, and the levels of these processes were not increased by addition of anti-CPS1 IgG or nonimmune (NI) IgG (Fig. 4). In contrast, significantly more neutrophils were associated with NJST258_2 (cps-2) following addition of anti-CPS2 IgG than were seen in control assays lacking CPS-specific antibody (e.g., 29.2% ± 1.4% of neutrophils in assays containing anti-CPS2 IgG had associated bacteria, compared with 6.6% ± 3.0% in assays containing NI IgG; P = 0.003) (Fig. 4A). In accordance with these data, anti-CPS2 IgG increased phagocytosis (ingestion) of NJST258_2 significantly (Fig. 4B).

We previously reported that any ST258 isolates ingested by human neutrophils were readily destroyed, albeit phagocytosis was limited under those assay conditions (18). To determine whether killing of our representative cps-1 and cps-2 ST258 isolates by neutrophils would be reflected by the phagocytosis results (Fig. 4), we evaluated

**FIG 4** CPS-specific antibody promotes binding and phagocytosis of ST258 by human neutrophils. (A) Association of ST258 isolate 50219 (cps-1) or isolate NJST258_2 (cps-2) with human neutrophils with or without 5% NHS in the absence (None) or presence of 100 μg/ml anti-CPS1 IgG, anti-CPS2 IgG, or nonimmune (NI) IgG was determined as described in Materials and Methods. Data are expressed as the percentages of neutrophils that had associated bacteria, which includes surface-bound and ingested bacteria. (B) Phagocytosis of ST258 isolates by human neutrophils was determined using fluorescence microscopy as described in Materials and Methods. Phagocytosis data are expressed as the percentages of associated bacteria (bound plus ingested) that were intracellular. The assays described in the legends for panels A and B were performed at a ratio of 1 CFU per neutrophil, and results are presented as means ± SEM from three separate experiments. *, P < 0.05 (as determined with repeated-measures one-way ANOVA and Tukey’s posttest). Unop, unopsonized (no serum added).
bacterial survival during phagocytic interactions with human neutrophils with or without CPS-specific antibody (Fig. 5; see also Fig. S2). Consistent with the ability of NHS alone to promote phagocytosis of the ST258 cps-1 isolate, bacterial survival was reduced significantly by the activity of human neutrophils in the presence of NHS (survival was 30.4% ± 3.0% for assays that included the use of NHS versus 131.7% ± 18.3% for assays lacking NHS) (Fig. 5A). This neutrophil bactericidal activity was not augmented by addition of anti-CPS1 IgG (Fig. 5A), a finding that was not surprising to us given the relatively high level of bacterial killing by neutrophils under these assay conditions. It is possible that the naturally occurring CPS1-specific antibodies present in the NHS from our pool of healthy blood donors were sufficient to promote optimal uptake of the cps-1 ST258 isolate tested here (Fig. S1). Such a hypothesis is in general consistent with a similar phenomenon known to occur for Staphylococcus aureus (i.e., NHS contains naturally occurring S. aureus antibodies and in turn promotes phagocytosis), another human commensal organism and opportunistic pathogen. In contrast to the results determined with the cps-1 ST258 isolate, the presence of NHS alone failed to promote significant killing of the cps-2 isolate (NJST258_2) by human neutrophils (Fig. 5B). Most notably, survival of NJST258_2 was reduced significantly by addition of anti-CPS2 IgG to neutrophil assays containing NHS (survival was 93.4% ± 13.5% for assays containing NI IgG compared with 43.3% ± 4.8% for those with anti-CPS2 IgG; \(P = 0.0007\)) (Fig. 5B). These results demonstrate that CPS-specific antibodies promote phagocytosis and killing of carbapenem-resistant ST258 K. pneumoniae.

**Concluding remarks.** Infections caused by antibiotic-resistant bacteria represent a major problem globally. There is continued emergence and reemergence of antibiotic-resistant bacteria, including carbapenem-resistant K. pneumoniae. For example, ceftazidine-avibactam was shown recently to be effective for treatment of carbapenem-resistant K. pneumoniae (32, 33), but, as with many antibiotics, resistance can develop during treatment (34). Therefore, new preventive or therapeutic approaches are needed. Immunophrophylaxis and immunotherapy approaches based on the use of anti-CPS antibodies or hyperimmune intravenous immunoglobulin (IVIG) from patients immunized with Klebsiella CPS were developed in the 1980s and 1990s (35–38). Importantly, such approaches circumvent the problem of antibiotic resistance. The anti-CPS vaccine approached worked well to protect rodents from death in experimental models of severe K. pneumoniae infection (39, 40). The vaccine was evaluated for safety in humans (35), and the use of CPS-specific hyperimmune IVIG decreased the incidence and severity of Klebsiella infections in a human clinical trial.
Previous work also demonstrated that vaccines (either monovalent or polyvalent) can protect against multiple (as many as 71) *Klebsiella* capsule types (35, 42). The majority of ST258 clinical isolates in the United States and many other regions of the world are composed of one of only two capsule polysaccharide types (*cps*-1 or *cps*-2) (10, 13, 15, 17). Therefore, as a starting point, a vaccine that targets the most prominent strains of carbapenem-resistant *K. pneumoniae* need be effective only against *cps*-1 and *cps*-2 strains. The number of *cps* types to be included in a potential vaccine could then be expanded based on clinical and molecular epidemiology. Here we show a proof of concept for an immunotherapy approach that could be developed for prevention or treatment of carbapenem-resistant ST258 *K. pneumoniae* infections. It is noteworthy that our results were obtained using serum and neutrophils obtained from healthy individuals, who are not susceptible to ST258 infections in general. Thus, the effective ability of anti-CPS antibody to promote killing of ST258 might be increased in the susceptible host (e.g., an individual with comorbidities or immunosuppression). An immunotherapy approach for *K. pneumoniae* could be extended to target lineages other than ST258, and such work is ongoing (43, 44). Moreover, recent studies indicated that antibodies specific for *K. pneumoniae* lipopolysaccharide work synergistically with antibiotics to improve outcomes in mouse infection models (20). Such an approach could be adapted for use with antibodies specific for CPS or with a combination of antibodies specific for CPS and lipopolysaccharide. It will be important in future studies to test the ability of this immunotherapy approach to protect against severe disease or death in animal infection models.

**MATERIALS AND METHODS**

**Bacterial strains and culture.** *Klebsiella pneumoniae* isolates NJST258_1 (*cps*-2), NJST258_2 (*cps*-2), 33576/1793 (*cps*-1), 34446/1805 (*cps*-1), 29940/1775 (*cps*-1), and 50219/1787 (*cps*-1) were reported and/or characterized previously (12, 18, 19). Three of these strains/clinical isolates (NJST258_1, NJST258_2, and 34446) were tested previously in a serum bactericidal activity assay. We demonstrated previously that NJST258_1 is serum sensitive (survival is ~25% in 5% NHS) relative to NJST258_2 and 34446, which survive fully under the same assay conditions. After considering serum sensitivity and resistance, we selected isolates 50219 and NJST258_2 for generation of rabbit antiserum because these isolates are representative of ST258 clades 1 and 2, which constitute the majority of carbapenem-resistant *Klebsiella pneumoniae* isolates from selected health care facilities in the United States (13). Isolate 33576 is a carbapenem-susceptible ST258 clinical isolate (*cps*-2) that was used to generate the isogenic capsule polysaccharide mutant (Δ*wzy*) and complemented mutant (cΔ*wzy*) strains (see below for details). Bacteria from frozen stocks were inoculated into Luria-Bertani (LB) broth and cultured overnight with shaking at 37°C. Cultures were diluted 1:200 into fresh media the following day and cultured to the desired phase of growth.

A Red/ET recombination system was used to generate an ST258 isogenic *wzy* deletion strain (the Δ*vwy* mutant) according to the manufacturer’s protocol (Quick and Easy *Escherichia coli* gene deletion kit; Gene Bridges, Heidelberg, Germany), but with slight modification. Briefly, a linear DNA fragment, i.e., an FRT-PGK-gb2-arr3-FRT cassette (rifampin resistance gene cassette) with 50-bp arms homologous to DNA upstream and downstream of *wzy*, was amplified by PCR and used to replace *wzy* in *K. pneumoniae* isolate 33576. Positive transformants were confirmed by using gene-specific primers. Complementation of the Δ*wzy* strain was conducted by cloning *wzy* from the wild-type strain into a pGlow vector (Invitrogen), followed by electroporation into the Δ*wzy* strain.

**Ethics statement and isolation of human neutrophils.** Venous blood or heparinized venous blood was obtained from healthy volunteers in accordance with a protocol approved by the Institutional Review Board for Human Subjects at the National Institute of Allergy and Infectious Diseases (protocol 01-I-N055). All volunteers gave informed consent prior to participation in the study. Human neutrophils were isolated from heparinized human blood using a standard method, which includes dextran sedimentation followed by Hypaque-Ficoll gradient centrifugation as previously described (45, 46). Granulocytes comprised 99.1% ± 0.3% of the leukocytes in the neutrophil preparations (sampled over a 1-month period), and viability was >99% as assessed by flow cytometry (FACSCelesta; BD Biosciences) as reported previously (45).

**Purification and analysis of capsule polysaccharide.** *K. pneumoniae* capsule polysaccharide was extracted and purified using two separate published methods with some modifications. For immunization of rabbits, CPS was extracted essentially as reported by Cunha et al. (15). Fractions containing CPS peaks (as determined by a standard uronic acid assay) were pooled, and further with a HiLoad 16/600 Superdex 200 gel filtration column (GE Healthcare Life Sciences, Pittsburgh, PA). Fracations containing CPS peaks (as determined by a standard uronic acid assay) were pooled, and...
the buffer was changed to 0.9% injection-grade saline solution by using a Centrifcon Plus-70 filter unit (EMD Millipore) (molecular weight cutoff [MWCO], 100,000). The amount of endotoxin in each CPS preparation was determined with a kit assay (QCL-1000 end point chromogenic LAL assay) as described by the manufacturer (Lonza Inc.).

For analysis of CPS composition, CPS was extracted from culture supernatants using the method of Cryz et al. (48). Bacteria were cultured for 16 h in 250 ml HYEM medium (2% [wt/vol] Hy-Case SF, 0.3% [wt/vol] yeast extract, 2% [wt/vol] maltose) at 37°C with shaking and then pelleted by centrifugation at 8,000 × g for 30 min. Supernatant was aspirated and filtered using a 0.22-μm-pore-size polyethersulfone (PES) filter. CPS was precipitated with N-cetyl-N,N,N-trimethylammonium bromide (CETAB) (0.5% final concentration) at room temperature (RT) for 30 min with stirring. Samples were centrifuged at 4,200 × g for 30 min, supernatant was aspirated, and CPS was dissolved in 50 ml 1 M CaCl₂. CPS was precipitated by addition of 200 ml (80% [vol/vol]) ethanol. Samples were centrifuged again at 4,200 × g for 30 min, and CPS pellets were dissolved in 25 to 50 ml H₂O. CPS was concentrated as needed by using a Centrifcon Plus-70 filter unit and stored at 4°C until used. CPS preparations were then analyzed by gas chromatography and mass spectrometry, size exclusion chromatography, and nuclear magnetic resonance (NMR) spectroscopy at the Complex Carbohydrate Research Center, University of Georgia, Atlanta, GA (see Table S1 in the supplemental material).

Production of rabbit antibody. The animal protocol used for these studies was reviewed and approved by the Institutional Animal Care and Use Committee, Rocky Mountain Laboratories, NIAID/NIH (protocol RML 2017-004). In brief, New Zealand white rabbits (2 to 4 kg each) were inoculated with up to 500 μg purified K. pneumoniae CPS–5.0 ml pharmaceutical grade saline solution mixed 1:1 with TiterMax Gold adjuvant (Sigma-Aldrich). The CPS/TiterMax Gold inoculum was administered with a 23-gauge needle as follows: 0.05 ml was injected intramuscularly into each hind leg of each rabbit, and 0.1 ml was injected subcutaneously into 4 sites behind the shoulders and along the back. Each rabbit received an inoculum of 0.5 ml in total, which could include up to 10 μg K. pneumoniae endotoxin (lipopolysaccharide) per rabbit. Rabbits were subjected to boosting without TiterMax Gold every 3 to 4 weeks using the same immunization procedure as that described above. Blood and serum were collected prior to initial immunization (preimmune serum) and after each boost. Nonimmune (NI) serum was also collected from healthy rabbits that were not immunized. Serum was prepared according to standard methods, and aliquots were frozen at −80°C until use. Serum from rabbits immunized with CPS1 or CPS2 was labeled anti-CPS1 or anti-CPS2, respectively.

IgG was purified from anti-CPS1 or anti-CPS2 and NI serum using a protein G HP SpinTrap column according to the instructions of the manufacturer (GE Healthcare Life Sciences). Antibody was concentrated using an Amicon Ultra-15 centrifugal filter unit (Millipore Sigma, Burlington, MA) (10K MWCO) and treated using an Amicon Ultra-15 centrifugal filter unit (Millipore Sigma, Burlington, MA) (10K MWCO) and stored at −80°C until use. Serum from rabbits immunized with CPS1 or CPS2 was labeled anti-CPS1 or anti-CPS2, respectively.

IgG was purified from anti-CPS1 or anti-CPS2 and NI serum using a protein G HP SpinTrap column according to the instructions of the manufacturer (GE Healthcare Life Sciences). Antibody was concentrated using an Amicon Ultra-15 centrifugal filter unit (Millipore Sigma, Burlington, MA) (10K MWCO) and suspended in sterile Dulbecco's phosphate-buffered saline (DPBS) to the desired volume, and IgG levels were measured using a Pierce bichinonic acid (BCA) protein assay kit (Thermo, Fisher Scientific, Waltham, MA).

Detection of surfaced-expressed CPS with flow cytometry. Bacteria were cultured to the mid-logarithmic or late stationary (overnight) phase of growth in LB broth. Aliquots (200 μl) of culture were pelleted by centrifugation (2,400 × g for 4 min at RT), washed in DPBS, and suspended in 500 μl DPBS containing 2% (wt/vol) bovine serum albumin (blocking buffer) on ice for 60 min. Bacteria were pelleted again by centrifugation and then resuspended in 500 μl DPBS. Aliquots (100 μl) of bacteria were combined with 100 μl of prediluted (1:1,000) anti-CPS1, anti-CPS2, or preimmune serum (1:2,000 final dilution) and incubated on ice for 30 min. Alternatively, bacteria were incubated on ice for 30 min with IgG (5 μg/ml) purified from anti-CPS1, anti-CPS2, or NI serum. Samples were diluted with 800 μl wash buffer (0.8% bovine serum albumin [BSA]–DPBS), and bacteria were pelleted as described above. Bacteria were resuspended in 100 μl of prediluted (1:500 in DPBS) secondary antibody, i.e., AffiniPure F(Ab)₂ fragment goat anti-rabbit IgG (H+L) conjugated to fluorescein isothiocyanate (FITC) (Jackson Immunoresearch, West Grove, PA), and incubated on ice for 30 min. At the end of the incubation period, 800 μl of wash buffer was added to each tube, and bacteria were pelleted by centrifugation and resuspended in 200-μl wash buffer. Bacteria were analyzed by flow cytometry (FACSCelesta flow cytometer; BD Biosciences).

Antibody titers were determined using live bacteria combined with flow cytometry. The titers of anti-CPS1 and anti-CPS2 were determined according to the greatest dilution at which there was still a difference in surface binding compared to rabbit NI serum (negative control; 1:2,000). The presence of CPS-specific antibody in NHS was measured as described above, except AffiniPure F(Ab)₂ fragment goat anti-human IgG (H+L) or goat anti-human IgG plus IgM (H+L) conjugated with FITC (Jackson Immunoresearch) was used as the secondary antibody.

Serum bactericidal activity. Survival of bacteria in normal human serum (NHS) was determined using a published method (19). Assays for serum bactericidal activity were performed using NHS that was either prepared fresh or frozen once and thawed for use. Survival of the wild-type, Δwzy, and cΔwzy ST258 strains was determined in 100% NHS for 30 min at 37°C. The ability of anti-CPS1 or anti-CPS2 (diluted 1:100 in NHS; 1% final concentration) or of anti-CPS IgG to augment human serum bactericidal activity was determined using 5% to 25% NHS as indicated. Bacteria (~2 × 10⁶ CFU/ml) were combined with NHS and either 1% rabbit preimmune or immune serum or with anti-CPS IgG in RPMI medium to reach a final volume of 0.6 ml. Assay tubes were rotated gently for 1 h at 37°C. Aliquots from each assay tube were plated on LB, and colonies were enumerated the following day.

Neutrophil phagocytosis and bactericidal activity. Human neutrophil phagocytosis and bactericidal activity were determined using a published method (18), but with modifications.
Two separate assays were used to measure phagocytosis and killing of bacteria by human neutrophils. We used a published synchronized phagocytosis assay to determine the levels of phagocytosis and killing of wild-type and Δwzy and cΔwzy ST258 strains (18). Bacteria, used at a ratio of ~10 CFU per neutrophil, were not opsonized with NHS for these assays, because the Δwzy mutant would be killed by serum complement and this would confound interpretation of the results. We used a synchronized phagocytosis assay for these experiments because phagocytosis is optimal under these conditions (i.e., neutrophils are semiadherent and primed, and bacteria are in close proximity or in contact).

To measure the ability of antibody to promote polymorphonuclear leukocyte (PMN) bactericidal activity, we used a suspension phagocytosis assay. In brief, bacteria were left unopsonized or were preincubated with 5% NHS and 1% rabbit preimmune or immune serum or 5% NHS and 100 μg/ml anti-CPS IgG or NI IgG for 10 min at room temperature in RPMI 1640 medium, HEPES (RPMI/H). Human PMNs were added to the assay mixtures at a 1:1 CFU-to-PMN ratio, and samples (0.6 ml final volume) were rotated gently for 1 h at 37°C. At the designated time, 0.1% saponin was added to the assay mixtures, which were then chilled on ice for 15 min to permeabilize and lyse PMNs. Aliquots of assay mixtures were plated on LB to determine CFU data. Percent survival was determined with the following equation: percent survival = CFU_{PMN}/CFU_{PMN} × 100.

**Statistics.** Statistical analysis was performed with GraphPad Prism version 7.03 (GraphPad Software, Inc.). To determine data for comparisons of 2 or more samples, data were analyzed using one-way analysis of variance (ANOVA) or repeated-measures one-way ANOVA and Dunnett’s or Tukey’s posttest as indicated. Comparisons of 2 samples were made using a two-tailed Student’s t test.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.00297-18.

**FIG S1,** TIF file, 2.2 MB.  
**FIG S2,** TIF file, 0.7 MB.  
**TABLE S1,** DOCX file, 0.01 MB.

**ACKNOWLEDGMENTS**

S.D.K., B.N.K., and F.R.D. conceived and designed the study. B.N.K., R.P., and L.C. provided all bacterial strains and clinical isolates. A.R.P., B.F., and S.D.K. performed the experiments. A.R.P., S.D.K., and F.R.D. performed all of the data analyses and verification of data analyses. F.R.D. drafted the manuscript text and assembled the figures. The manuscript text was edited by S.D.K., A.R.P., and B.N.K., and all of us reviewed the final text.

The capsule polysaccharide analyses were supported by the Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences, U.S. Department of Energy (grant DE-SC0015662) to Parastoo Azadi at the Complex Carbohydrate Research Center, University of Georgia. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (F.R.D.), and by grants from the National Institutes of Health (R01AI090155 to B.N.K. and R21AI117338 to L.C.). The funder had no direct role in the design of the study, collection or interpretation of data, or the decision to submit the work for publication.

**REFERENCES**

1. Magill SS, Edwards JR, Babemg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. 2014. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:1198–1208. https://doi.org/10.1056/NEJMoa1306801.

2. Munoz-Price LS, Poiré L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kouragiasamy K, Livermore DM, Maya JJ, Nordmann P, Paterson JB, Patel JB, Paterson DL, Pitout JD, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. Lancet Infect Dis 13:785–796. https://doi.org/10.1016/S1473-3099(13)70190-7.

3. Cuzon G, Naas T, Truong H, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the worldwide diversity of *Klebsiella pneumoniae* carbapenemases. Emerg Infect Dis 20:1170–1175. https://doi.org/10.3201/eid2007.121004.

4. Cerqueira GC, Earl AM, Ernst CM, Grad YH, Dekker JP, Feldgarden M, Chapman SB, Reis-Cunha JL, Shea TP, Young S, Zeng Q, Delaney ML, Kim D, Peterson EM, O’Brien TF, Ferraro MJ, Hooper DC, Huang SS, Kirby JE, Onodondon AB, Birren BW, Hung DT, Cosimi LA, Wortman JR, Murphy CI, Antimicrob Agents Chemother 59:5873–5884. https://doi.org/10.1128/AAC.01019-15.

5. Alicino C, Giacobbe DR, Orsi A, Tassinari F, Trucchi C, Sarteschi G, Copello F, Del Bono V, Viscoli C, Icardi G. 2015. Trends in the annual incidence of carbapenem-resistant *Klebsiella pneumoniae* bloodstream infections: a 8-year retrospective study in a large teaching hospital in northern Italy. BMC Infect Dis 15:415. https://doi.org/10.1186/s12879-015-1152-0.

6. Falagas ME, Tansari GS, Karageorgopoulos DE, Vardakas KZ. 2014. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175. https://doi.org/10.3201/eid2007.121004.

7. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. 2012. Outcome of carbapenem resistant *Klebsiella pneumoniae* bloodstream infections. Clin Microbiol Infect 18:54–60. https://doi.org/10.1111/j.1469-0691.2011.03478.x.

8. Cerqueira GC, Earl AM, Ernst CM, Grad YH, Dekker JP, Feldgarden M, Chapman SB, Reis-Cunha JL, Shea TP, Young S, Zeng Q, Delaney ML, Kim D, Peterson EM, O’Brien TF, Ferraro MJ, Hooper DC, Huang SS, Kirby JE, Onodondon AB, Birren BW, Hung DT, Cosimi LA, Wortman JR, Murphy CI,
Hall HE, Humphries JC. 1958. The relationship between insusceptibility to oophorophagocytosis in Klebsiella pneumoniae. Infect Immun 62:4495–4499.

Czyz SJ, Jr, Furer F, Germanier R. 1984. Experimental Klebsiella pneumoniae burn wound sepsis: role of capsular polysaccharide. Infect Immun 43:440–441.

Domenico P, Johanson WG, Jr, Straus DC. 1982. Lobar pneumonia in rats produced by clinical isolates of Klebsiella pneumoniae. Infect Immun 37:327–335.

Yoder Jr, 2011. Capsules of Streptococcus pneumoniae and other bacteria: paradigms for polysaccharide biosynthesis and regulation. Annu Rev Microbiol 65:563–581. https://doi.org/10.1146/annurev.micro.62.081307.162944.

Lin TL, Yang FL, Yang AS, Peng HP, Li TL, Tsai MD, Wu SH, Wang JT. 2012. Amino acid substitutions of MagA in Klebsiella pneumoniae affect the biosynthesis of the capsular polysaccharide. PLoS One 7:e46783. https://doi.org/10.1371/journal.pone.0046783.

Woodward R, Yi W, Li L, Zhao G, Eguchi H, Sridhar PR, Guo H, Song JK, Motari E, Cai L, Kelleher P, Liu X, Han W, Zhang W, Ding Y, Li M, Wang PG. 2010. In vitro bacterial polysaccharide biosynthesis: defining the functions of Wzy and Wzz. Nat Chem Biol 6:418–423. https://doi.org/10.1038/nchembio.351.

Yeh KW, Lin JC, Yin FY, Fung CP, Hung HC, Shu LK, Chang FY. 2010. Identification of two capsulartypes in epidemic KPC-producing Klebsiella pneumoniae sequence type 258 strains. Antimicrob Agents Chemother 61.

Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. 30 May 2017. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.00883-17.

van Duijn D, Lok JJ, Easly M, Cober E, Richter SS, Perez F, Salata RA, Klotz RN, Watkins RR, Doi Y, Kaye KS, Fowler VG, Jr, Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership Group. 2018. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163–171. https://doi.org/10.1093/cid/cix783.

Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen NT, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 in ST116-258 isolates during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61. https://doi.org/10.1128/AAC.02097-16.

Czyz SJ, Jr, Mortimer P, Cross AS, Furer E, Germanier R. 1986. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Vaccine 4:15–20. https://doi.org/10.1016/0264-410X(86)90092-7.

Czyz SJ, Jr, Furer E, Germanier R. 1985. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis 151:665–671. https://doi.org/10.1086/316651.

Czyz SJ, Jr, Furer E, Sadoff JC, Fredeking T, Que JU, Cross AS. 1991. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis 163:1055–1061. https://doi.org/10.1086/316533.

Czyz SJ, Jr, Furer E, Germanier R. 1986. Immunization against fatal experimental Klebsiella pneumoniae pneumonia. Infect Immun 54:403–407.

Czyz SJ, Jr, Furer E, Germanier R. 1984. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis 151:665–671. https://doi.org/10.1086/316651.

Czyz SJ, Jr, Furer E, Sadoff JC, Fredeking T, Que JU, Cross AS. 1991. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis 163:1055–1061. https://doi.org/10.1086/316533.

Czyz SJ, Jr, Furer E, Germanier R. 1986. Immunization against fatal experimental Klebsiella pneumoniae pneumonia. Infect Immun 54:403–407.

Czyz SJ, Jr, Furer E, Germanier R. 1984. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis 151:665–671. https://doi.org/10.1086/316651.

Czyz SJ, Jr, Furer E, Sadoff JC, Fredeking T, Que JU, Cross AS. 1991. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis 163:1055–1061. https://doi.org/10.1086/316533.

Czyz SJ, Jr, Furer E, Germanier R. 1986. Immunization against fatal experimental Klebsiella pneumoniae pneumonia. Infect Immun 54:403–407.

Czyz SJ, Jr, Furer E, Germanier R. 1984. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis 151:665–671. https://doi.org/10.1086/316651.

Czyz SJ, Jr, Furer E, Sadoff JC, Fredeking T, Que JU, Cross AS. 1991. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis 163:1055–1061. https://doi.org/10.1086/316533.

Czyz SJ, Jr, Furer E, Germanier R. 1986. Immunization against fatal experimental Klebsiella pneumoniae pneumonia. Infect Immun 54:403–407.

Czyz SJ, Jr, Furer E, Germanier R. 1984. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis 151:665–671. https://doi.org/10.1086/316651.

Czyz SJ, Jr, Furer E, Sadoff JC, Fredeking T, Que JU, Cross AS. 1991. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis 163:1055–1061. https://doi.org/10.1086/316533.
nosa infections. J Infect Dis 174:537–543. https://doi.org/10.1093/infdis/174.3.537.

42. Jones RJ, Roe EA. 1984. Vaccination against 77 capsular types of Klebsiella aerogenes with polyvalent Klebsiella vaccines. J Med Microbiol 18:413–421. https://doi.org/10.1099/00222615-18-3-413.

43. Diago-Navarro E, Calatayud-Baselga I, Sun D, Khairallah C, Mann I, Ulacia-Hernando A, Sheridan B, Shi M, Fries BC. 2017. Antibody-based immunotherapy to treat and prevent infection with hypervirulent Klebsiella pneumoniae. Clin Vaccine Immunol 24. https://doi.org/10.1128/CVI.00456-16.

44. Xiao X, Wu H, Dall’Acqua WF. 2016. Immunotherapies against antibiotics-resistant Klebsiella pneumoniae. Hum Vaccin Immunother 12:3097–3098. https://doi.org/10.1080/21645515.2016.1210746.

45. Kobayashi SD, Voyich JM, Buhl CL, Stahl RM, DeLeo FR. 2002. Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocytosis: cell fate is regulated at the level of gene expression. Proc Natl Acad Sci U S A 99:6901–6906. https://doi.org/10.1073/pnas.092148299.

46. Nauseef WM. 2007. Isolation of human neutrophils from venous blood. Methods Mol Biol 412:15–20. https://doi.org/10.1007/978-1-59745-467-4_2.

47. Domenico P, Schwartz S, Cunha BA. 1989. Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect Immun 57:3778–3782.

48. Cryz SJ, Jr, Furer E, Germanier R. 1985. Purification and vaccine potential of Klebsiella capsular polysaccharides. Infect Immun 50:225–230.